http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cce9ecc1c2b5cc50841594c5f698b7c0
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Romero |
| name | Pedro Romero |
| given-name | Pedro |
| organization-name | *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland;; ‡National Centres of Competence in Research Program on Molecular Oncology, Epalinges, Switzerland *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital of Lausanne, Lausanne, Switzerland; Translational Tumor Immunology Group, Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland 4Ludwig Institute for Cancer Research-Division of Oncology-Immunology, Lausanne, Switzerland; and 1Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland; *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland;; ¶Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland §Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, and **Ludwig Center for Cancer Research of the University of Lausanne, Lausanne 1066, Switzerland aFrom the Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland; and; †Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;; §National Center for Competence in Research, Molecular Oncology, Epalinges, Switzerland Translational Tumor Immunology Group, Ludwig Cancer Research, University of Lausanne, Lausanne, Switzerland; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland. Electronic address: pedro.romero@unil.ch. From the *Institute of Biochemistry, University of Lausanne and ‡Swiss Institute for Experimental Cancer Research, BIL Research Centre, CH-1066 Epalinges, Switzerland; the §Division for Clinical Onco-Immunology, Ludwig Institute for Cancer Research, CHUV, CH-1011 Lausanne, Switzerland; the ‖Division of Haematology, Geneva University Hospital, CMU, 1211 Geneva 14, Switzerland; and ¶Biogen, Inc., Department of Immunology and Inflammation, Cambridge, Massachusetts 02142 *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, and *Division of Clinical Oncoimmunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University Hospital of Lausanne, CH-1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University Hospital of Lausanne, CH-1011 Lausanne, Switzerland Center for Computational Biology and Bioinformatics, Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202, Molecular Kinetics, Inc., 6201 La Pas Trail, Suite 160, Indianapolis, Indiana 46268, School of Informatics, Indiana University-Purdue University at Indianapolis, 535 West Michigan Street, Indianapolis, Indiana 46202, and Institute for Biological Instrumentation, Russian Academy of Sciences, 142292 Pushchino, Moscow Region, Russia From the Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland; Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland; Multidisciplinary Oncology Center, University Hospital (CHUV), Lausanne, Switzerland; and Division of Immunology and Allergology, University Hospital of Geneva, Geneva, Switzerland. ∥Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland †Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne University Hospital (CHUV), Lausanne, Switzerland; and ∥Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Hôpital Orthopédique, Lausanne, Switzerland Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico Ludwig Institute for Cancer Research, Lausanne, Switzerland; Ludwig Cancer Research Center and Department of Oncology, and Bioinformatics Research Group, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA. Divisions of †Clinical Onco-Immunology, Ludwig Institute for Cancer Research, and Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital (Centre Hospitalier Universitare Vaudois), CH-1005 Lausanne, Switzerland; Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Hôpital Orthopédique, Lausanne, Switzerland From the *Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, Oxford, OX3 9DS, United Kingdom; and the ‡Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, 1011 Switzerland Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos 62250, Mexico Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, 1011 Lausanne, Switzerland Ludwig Cancer Research Center, Faculty of Biology and Medicine University of Lausanne Lausanne Switzerland †Ludwig Institute for Cancer Research, Lausanne University Hospital; *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, and Bioinformatics Research Group, SRI International, Menlo Park, California 94025 ‡Division of Clinical Onco-immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland; and Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, and Multidisciplinary Oncology Center, University Hospital, 1011 Lausanne, Switzerland; and Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, 1066 Epalinges, Switzerland From the *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, CH-1066 Epalinges, Switzerland; the ‡Institute of Molecular Medicine, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom; and the §Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland From the Providence Portland Medical Center, Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, and Oregon Health Sciences University, Portland, OR; Ludwig Institute for Cancer Research-Division of Oncology-Immunology, Lausanne, Switzerland; Data Management Services, Frederick Cancer Research and Development Center, National Cancer Institute, Frederick, MD; and Becton-Dickinson Biosciences, San Jose, CA. Department of Oncology, University of Lausanne, Lausanne, Switzerland *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland; *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland; Translational Tumor Immunology Group, Ludwig Cancer Research Center, University of Lausanne, Biopole III, CB02, Chemin des Boveresses 155, 1066, Epalinges, Switzerland. pedro.romero@unil.ch. Bioinformatics Research Group, SRI International, 333 Ravenswood Ave, Menlo Park, CA, 94025, USA *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland; *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital (Centre Hospitalier Universitaire Vaudois), Lausanne, Switzerland;; ‡National Center for Competence in Research, Molecular Oncology, Lausanne, Switzerland †Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, CHUV, Lausanne, Switzerland; Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital † Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland; and; ‡ National Center of Competence in Research Molecular Oncology Program of the Swiss National Science Foundation, Epalinges, Switzerland Division of Clinical Onco‐Immunology, Ludwig Institute for Cancer Research, University Hospital (CHUV) and National Center for Competence in Research (NCCR), Molecular Oncology Lausanne branch Lausanne Switzerland 3Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland; Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México (UNAM), Cuernavaca, Morelos 62210, Mexico Ludwig Institute for Cancer Research of the University of Lausanne, Epalinges, Switzerland Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, Switzerland. *Translational Tumor Immunology Group, Ludwig Center for Cancer Research, University of Lausanne, 1066 Epalinges, Switzerland; §Ludwig Center for Cancer Research, University of Lausanne, 1066 Epalinges, Switzerland; and Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Nocigenix Authors' Affiliation: Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland Departamento de Génetica del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico Ludwig Center for Cancer Research, University of Lausanne, Lausanne CH-1011, Switzerland; Instituto de Biotecnología, Universidad Nacional Autónoma de México, Colonia Chamilpa, Cuernavaca, México From the Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development SA, Immunology Department, Geneva, Switzerland; and the Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland. *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland;; ¶National Center for Competence in Research, Molecular Oncology, Epalinges, Switzerland; and Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, D.F. 04510, Mexico Translational Tumor Immunology Group Ludwig Center for Cancer Research Epalinges Switzerland †Ludwig Institute for Cancer Research, Division of Clinical Onco-Immunology, University Hospital and Lausanne Branch, Lausanne, Switzerland Departamento de Génetica y Fisiologı́a Molecular, Instituto de Biotecnologı́a, Universidad Nacional Autónoma de México, Cuernavaca, Morelos 62250, México aDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research and University of Lausanne, and Ludwig Center for Cancer Research of the University of Lausanne, CH-1011 Lausanne, Switzerland. From the *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, and the ‡Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland; and the §Institute of Molecular Medicine, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, CH-1066 Epalinges, Switzerland. 2Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland. §Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; and 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research and; 6National Center of Competence in Research Program on Molecular Oncology, Epalinges, Switzerland; Authors' Affiliations: 1Institute of Bioengineering, School of Life Sciences and School of Engineering; 2Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences; 3Institute for Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL); and 4Ludwig Center for Cancer Research, Université de Lausanne (UNIL), Lausanne, Switzerland *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital of Lausanne, Lausanne, Switzerland; 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital (CHUV), 1011 Lausanne, Switzerland Ludwig Center for Cancer Research of University of Lausanne, University of Lausanne, Lausanne, Switzerland Ludwig Center, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland Human Genetics of Infectious Diseases, Institut National de la Santé et de la Recherche Médicale (INSERM), U550, Faculty Necker, Paris 75015, France.; University Paris René Descartes, Paris 75015, France.; French-Chinese Laboratory of Genetics and Life Sciences, Rui Jin Hospital, Shanghai Jiao Tong University, Shanghai 200025, China.; Marseille-Luminy Immunology Institute, Marseille 13288, France.; Department of Genetics, INSERM, U781, Necker Hospital, Paris 75015, France. Center for Computational Biology and Bioinformatics, Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202, Molecular Kinetics, Inc., Indianapolis, Indiana 46268, School of Informatics, Indiana UniversityPurdue University, Indianapolis, Indiana 46202, and Institute for Biological Instrumentation, Russian Academy of Sciences, 142290 Pushchino, Moscow Region, Russia 1Centre of Excellence in Responsible Gaming, University of Gibraltar, Gibraltar, Gibraltar. *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, and †Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne University Hospital, Lausanne, Switzerland 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research Ltd., Lausanne Branch, Hôpital Orthopédique and; 3National Center for Competence in Research, Molecular Oncology and †Ludwig Center for Cancer Research of the University of Lausanne, 1011 Lausanne, Switzerland; Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, UNAM, Cuernavaca, Morelos 62210, Mexico Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland. †Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland; Department of Oncology UNIL-CHUV, Faculty of Biology and Medicine, University of Lausanne, Epalinges, Switzerland. Electronic address: pedro.romero@unil.ch. Authors' Affiliations: 1Translational Tumor Immunology Group, Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland; 2CIC-BT507, Institut Gustave Roussy, Villejuif, France; 3U1015 INSERM, Institut Gustave Roussy, Villejuif, France; 4Faculté de Médecine Paris Sud, Kremlin Bicêtre, France; 5Innate Pharma, Marseille, France; 6Département de Pathologie, Hôpital de Hautepierre, Strasbourg, France; 7Department of Pathology, Centre Hospitalier Universitaire, Rouen, France; 8U981 INSERM, Institut Gustave Roussy, Villejuif, France; 9UMR5201, Centre Léon Bérard, Lyon, France; and 10Centre d/Immunologie Marseille Luminy, Marseille, France Authors' Affiliations: 1Unité INSERM U753, Institut de Cancérologie Gustave Roussy, Villejuif Cedex, France; 2Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Santé), Luxembourg City, Luxembourg; 3Laboratory of Transcription Regulation, Department of Cell Biology, Nencki Institute, Warsaw, Poland; and 4Translational Tumor Immunology group, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland Ludwig Center for Cancer Research University Hospital Lausanne Switzerland Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland Molecular Kinetics Inc., 6201 La Pas Trail, Suite 160, Indianapolis, Indiana 46268, Center for Computational Biology and Bioinformatics, Department of Biochemistry and Molecular Biology, School of Medicine, Indiana University−Purdue University at Indianapolis, Indianapolis, Indiana 46202, School of Informatics, Indiana University−Purdue University at Indianapolis, Indianapolis, Indiana 46202, and Institute for Biological Instrumentation, Russian Academy of Sciences, 142292 Pushchino, Moscow Region, Russia 3Division of Clinical OncoImmunology, Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland; and Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital (CHUV), Lausanne, Switzerland. Departamento de Genética y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos 62250, Mexico 4Ludwig Cancer Research Center, Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. Authors' Affiliations: 1Unité INSERM U753, Institut de Cancérologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France; 2Translational Tumor Immunology group, Ludwig Center for Cancer Res of the University of Lausanne, Hôpital Orthopédique, Niveau 5 Est, Av. Pierre-Decker 4, CH-1011 Lausanne, Switzerland; 3Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health, Luxembourg City, Luxembourg; 4Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR6097, Sophia Antipolis, France †Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland;; ¶National Center of Competence in Research-Molecular Oncology, Epalinges, Switzerland Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland; §Division of Clinical Onco-Immunology, University Hospital (CHUV), Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland Department of Oncology UNIL CHUV, University of Lausanne , Lausanne , Switzerland Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland; and *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, 1Division of Clinical Onco-Immunology, University Hospital (CHUV), 1011 Lausanne, Switzerland *Ludwig Institute for Cancer Research, Lausanne Branch, Department of Fundamental Oncology, Ludwig Cancer Research Center, University of Lausanne, Epalinges, Vaud, Switzerland *Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland;; ‡Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland; Ludwig Cancer Research Center Department of Oncology Faculty of Biology and Medicine University of Lausanne Lausanne Switzerland 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research;; 4National Center for Competence in Research, Molecular Oncology, Epalinges, Switzerland Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Av. Universidad 2001 Cuernavaca Morelos 62210 Mexico From the *Centre d'Immunologie Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique de Marseille-Luminy, Case 906, 13288 Marseille, Cedex 09, France; and ‡Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, 1066 Epalinges, Switzerland Novigenix SA, 1066 Epalinges, Switzerland |
Incoming Links
Total number of triples: 504.